Skip to main content
Salarius Pharmaceuticals, Inc. logo

Salarius Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SLRX ISIN · US79400X4043 US Professional, scientific and technical activities
Filings indexed 699 across all filing types
Latest filing 2025-11-24 Director's Dealing
Country US United States of America
Listing US SLRX

About Salarius Pharmaceuticals, Inc.

https://salariuspharma.com/

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for cancer patients with high unmet medical needs. The company's core technology focuses on correcting the dysregulated gene expression of cancer cells, a key driver of disease development. Its pipeline includes two classes of drugs: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). The lead TPI candidate, seclidemstat (SP-2577), is in Phase 1/2 clinical trials, while the lead TPD candidate, SP-3164, is in IND-enabling studies. These therapeutic candidates are being developed to treat solid and hematologic cancers, including leukemias and lymphomas.

Recent filings

Filing Released Lang Actions
FORM 3
Director's Dealing
2025-11-24 English
FORM 3
Director's Dealing
2025-11-24 English
FORM 4
Director's Dealing
2025-11-20 English
8-K
Regulatory Filings
2025-11-19 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-18 English
8-K
Regulatory Filings
2025-11-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.